drugset / Trial / NCT00081263

Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00081263 ↗

RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase II trial studies how well celecoxib works in treating patients with cervical intraepithelial neoplasia, a precancerous lesion of the cervix which can develop into cervical cancer. Celecoxib may be effective in preventing the development of cervical cancer in patients who have cervical intraepithelial neoplasia.

Timeline

Start
2005-06
Primary completion
2012-09
Completion
—

Outcome

Missed primary endpoint

paper In primary analysis, histologic regression was not significantly higher in the celecoxib group (40%) than in the placebo group (34.1%). PMID 28285845 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 400 mg Oral